MEDP Medpace Holdings, Inc.
USHealthcareAs of 2026-10-08
Why MEDP matters now
Medpace Holdings, Inc. (MEDP) is a US stock in Healthcare. The latest InvestLog snapshot shows $602.70 with -0.26% on the session and $16.82B in market capitalization; recent performance reads 1-month +9.59% and YTD -18.06%.
The latest financial table shown here is Q1 2026, with revenue of $706.6M, net income of $123.9M, and EPS of $4.28. Investors can compare that operating picture with valuation signals such as P/E 31.99 and FCF yield 5.6%.
InvestLog's latest related AI research is a Insider Sale note titled "Troendle August J. sells $30.3M of MEDP". The latest indexable market news headline is "Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $484.00; recent insider activity includes Hansman Brad W. filing ; recent congressional disclosure data includes David Taylor Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
31.99
PEG
2.77
P/B
21.88
P/S
4.91
EV/EBITDA
21.02
DCF Value
$428.89
FCF Yield
5.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
29.1%
Operating Margin
21.0%
Net Margin
17.2%
ROE
120.9%
ROA
21.6%
ROIC
57.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $706.6M | $123.9M | $4.28 |
| Q4 2025 | $708.5M | $135.1M | $4.67 |
| FY 2025 | $2.53B | $451.1M | $15.28 |
| Q3 2025 | $659.9M | $111.1M | $3.87 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$498.86
Target (Median)
$484.00
Target Range
$400.00 - $582.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
Troendle August J. sells $30.3M of MEDPTroendle August J. 内部减持 MEDP $30.3M
Troendle August J. (Director, Officer, 10% Owner, President & CEO) sold 48,667 shares of Medpace Holdings, Inc.Troendle August J.（Director, Officer, 10% Owner, President & CEO）于 2026-09-29 至 2026-09-30 卖出 Medpace Holdings, Inc.（MEDP）48,667 股，平均价格 $623.03，合计约 $30.3M。该交易于 2026-10-01 通过 SEC 原始 Form 4 披露。
Troendle August J. sells $27.4M of MEDPTroendle August J. 内部减持 MEDP $27.4M
Troendle August J. (director, 10 percent owner, officer: President & CEO) sold 43,916 shares of Medpace Holdings, Inc.Troendle August J.（director, 10 percent owner, officer: President & CEO）于 2026-09-23 至 2026-09-24 卖出 Medpace Holdings, Inc.（MEDP）43,916 股，平均价格 $624.01，合计约 $27.4M。该交易于 2026-09-25 通过 SEC 原始 Form 4 披露。
Troendle August J. sells $44.4M of MEDPTroendle August J. 内部减持 MEDP $44.4M
Troendle August J. (director, 10 percent owner, officer: President & CEO) sold 70,901 shares of Medpace Holdings, Inc.Troendle August J.（director, 10 percent owner, officer: President & CEO）于 2026-09-21 至 2026-09-22 卖出 Medpace Holdings, Inc.（MEDP）70,901 股，平均价格 $626.62，合计约 $44.4M。该交易于 2026-09-23 通过 SEC 原始 Form 4 披露。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.18
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.